Researchers at Albert Einstein College of Medicine reported a manufacturing approach that uses a tricytokine fusion scaffold (IL‑7/IL‑15/IL‑21) to generate CAR‑T cells enriched for long‑lived T memory stem cells, producing more durable disease control in mouse models, the team published in Science Advances. The scaffold approach increases the fraction of self‑renewing cells and improved in vivo persistence compared with standard activation protocols. The method is presented as a manufacturable change to cell production rather than a new drug substance, potentially simplifying clinical translation. Developers of CAR‑T for hematologic malignancies and infectious diseases will evaluate whether the scaffold improves clinical durability and reduces relapse, and how the approach interacts with existing safety management for cytokine‑related toxicities.